Treatment Algorithms Insight Series

 

 

 

Key Users

U.S. Market Research
Global Market Research
Brand Management
Commercial Analysis

 

 

Quantifying Lines of Therapy through Primary Research and Patient-Level Data

• Download brochure
• Download 2010 report titles
• Download methodology

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS LifeLink: Health Plan Claims database to provide exceptional insight into physicians’ prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

Treatment Algorithms Insight Series reports deliver real value by examining physicians’ actual prescribing behavior as they initiate therapy and move through second- and third-line choices.  Our analysis is driven by the largest and most complete longitudinal patient-level database available. This database examines the prescribing practices for 61 million patients from more than 98 health plans, providing the most representative sample of U.S. treatment practice.

For each disease examined, Decision Resources’ Treatment Algorithms Insight Series provides the following:

• Qualitative diagnosis and referral patterns for the United States based on thought leader input and guideline recommendations
• Quantitative treatment algorithms based on patient-level claims data
• Product share (class and specific compound level) within each line of therapy(1st, 2nd, 3rd line)
• Practicing physician opinion on why specific drugs are chosen for certainpatient populations
• Discussion of key drug combinations (including add versus switch patterns) by lines of therapy
• Progression of therapy from key 1st line products (e.g., initial treatment w/Advair to 2nd line, 3rd line; initial treatment with Spiriva to 2nd line, 3rd line)
• Pathway to key therapies from previous therapies (e.g., how much Humira use is preceded by Enbrel versus methotrexate?)
• Qualitative analysis of 2-year forecast incorporating practicing physician sentiment towards upcoming launches, changes in reimbursement, etc

To provide this level of analysis, we first examine the patient-level data and then survey 150 physicians, including primary care physicians and the appropriate specialists, to discover the reasoning behind the actual prescribing behavior. Our insight clarifies the treatment patterns and tell you why a drug achieves its patient share within each line of therapy.